Literature DB >> 30920879

Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.

Sarat Chandarlapaty1, Pedram Razavi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30920879      PMCID: PMC6506417          DOI: 10.1200/JCO.19.00090

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  30 in total

1.  Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

Authors:  J L Dean; C Thangavel; A K McClendon; C A Reed; E S Knudsen
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

2.  The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element.

Authors:  J A DeCaprio; J W Ludlow; D Lynch; Y Furukawa; J Griffin; H Piwnica-Worms; C M Huang; D M Livingston
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

3.  NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Authors:  Cynthia X Ma; Feng Gao; Jingqin Luo; Donald W Northfelt; Matthew Goetz; Andres Forero; Jeremy Hoog; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Karen S Anderson; Julie Margenthaler; Rebecca Aft; Timothy Hobday; Timothy Moynihan; William Gillanders; Amy Cyr; Timothy J Eberlein; Tina Hieken; Helen Krontiras; Zhanfang Guo; Michelle V Lee; Nicholas C Spies; Zachary L Skidmore; Obi L Griffith; Malachi Griffith; Shana Thomas; Caroline Bumb; Kiran Vij; Cynthia Huang Bartlett; Maria Koehler; Hussam Al-Kateb; Souzan Sanati; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2017-03-07       Impact factor: 12.531

4.  Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Authors:  Kelly K Hunt; Khandan Keyomarsi; Cansu Karakas; Min Jin Ha; Anna Biernacka; Min Yi; Aysegul A Sahin; Opoku Adjapong; Gabriel N Hortobagyi; Melissa Bondy; Patricia Thompson; Kwok Leung Cheung; Ian O Ellis; Sarah Bacus; W Fraser Symmans; Kim-Anh Do
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

5.  Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Authors:  Rinath Jeselsohn; Roman Yelensky; Gilles Buchwalter; Garrett Frampton; Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo; Jaime Ferrer-Lozano; Jose A Perez-Fidalgo; Massimo Cristofanilli; Henry Gómez; Carlos L Arteaga; Jennifer Giltnane; Justin M Balko; Maureen T Cronin; Mirna Jarosz; James Sun; Matthew Hawryluk; Doron Lipson; Geoff Otto; Jeffrey S Ross; Addie Dvir; Lior Soussan-Gutman; Ido Wolf; Tamar Rubinek; Lauren Gilmore; Stuart Schnitt; Steven E Come; Lajos Pusztai; Philip Stephens; Myles Brown; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2014-01-07       Impact factor: 12.531

6.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Authors:  Debu Tripathy; Seock-Ah Im; Marco Colleoni; Fabio Franke; Aditya Bardia; Nadia Harbeck; Sara A Hurvitz; Louis Chow; Joohyuk Sohn; Keun Seok Lee; Saul Campos-Gomez; Rafael Villanueva Vazquez; Kyung Hae Jung; K Govind Babu; Paul Wheatley-Price; Michelino De Laurentiis; Young-Hyuck Im; Sherko Kuemmel; Nagi El-Saghir; Mei-Ching Liu; Gary Carlson; Gareth Hughes; Ivan Diaz-Padilla; Caroline Germa; Samit Hirawat; Yen-Shen Lu
Journal:  Lancet Oncol       Date:  2018-05-24       Impact factor: 41.316

7.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

Authors:  Dennis J Slamon; Patrick Neven; Stephen Chia; Peter A Fasching; Michelino De Laurentiis; Seock-Ah Im; Katarina Petrakova; Giulia Val Bianchi; Francisco J Esteva; Miguel Martín; Arnd Nusch; Gabe S Sonke; Luis De la Cruz-Merino; J Thaddeus Beck; Xavier Pivot; Gena Vidam; Yingbo Wang; Karen Rodriguez Lorenc; Michelle Miller; Tetiana Taran; Guy Jerusalem
Journal:  J Clin Oncol       Date:  2018-06-03       Impact factor: 44.544

8.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

9.  Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

Authors:  Barbie Taylor-Harding; Paul-Joseph Aspuria; Hasmik Agadjanian; Dong-Joo Cheon; Takako Mizuno; Danielle Greenberg; Jenieke R Allen; Lindsay Spurka; Vincent Funari; Elizabeth Spiteri; Qiang Wang; Sandra Orsulic; Christine Walsh; Beth Y Karlan; W Ruprecht Wiedemeyer
Journal:  Oncotarget       Date:  2015-01-20

10.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Pankaj Vats; Fengyun Su; Robert J Lonigro; Xuhong Cao; Shanker Kalyana-Sundaram; Rui Wang; Yu Ning; Lynda Hodges; Amy Gursky; Javed Siddiqui; Scott A Tomlins; Sameek Roychowdhury; Kenneth J Pienta; Scott Y Kim; J Scott Roberts; James M Rae; Catherine H Van Poznak; Daniel F Hayes; Rashmi Chugh; Lakshmi P Kunju; Moshe Talpaz; Anne F Schott; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

View more
  7 in total

1.  Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.

Authors:  Zijie Cai; Jingru Wang; Yudong Li; Qianfeng Shi; Liang Jin; Shunying Li; Mengdi Zhu; Qi Wang; Lok Lam Wong; Wang Yang; Hongna Lai; Chang Gong; Yandan Yao; Yujie Liu; Jun Zhang; Herui Yao; Qiang Liu
Journal:  Sci China Life Sci       Date:  2022-08-11       Impact factor: 10.372

Review 2.  The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review.

Authors:  Shafighe Asgari-Karchekani; Armin Aryannejad; Seied Asadollah Mousavi; Shirin Shahsavarhaghighi; Seyed Mohammad Tavangar
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

3.  Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.

Authors:  Inga-Marie Schaefer; Matthew L Hemming; Meijun Z Lundberg; Matthew P Serrata; Isabel Goldaracena; Ninning Liu; Peng Yin; Joao A Paulo; Steven P Gygi; Suzanne George; Jeffrey A Morgan; Monica M Bertagnolli; Ewa T Sicinska; Chen Chu; Shanshan Zheng; Adrian Mariño-Enríquez; Jason L Hornick; Chandrajit P Raut; Wen-Bin Ou; George D Demetri; Sinem K Saka; Jonathan A Fletcher
Journal:  Br J Cancer       Date:  2022-09-29       Impact factor: 9.075

Review 4.  Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?

Authors:  Athanasios Mavratzas; Frederik Marmé
Journal:  Breast Care (Basel)       Date:  2021-02-24       Impact factor: 2.860

Review 5.  Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.

Authors:  Xia-Qing Xu; Xiao-Hui Pan; Ting-Ting Wang; Jian Wang; Bo Yang; Qiao-Jun He; Ling Ding
Journal:  Acta Pharmacol Sin       Date:  2020-06-05       Impact factor: 6.150

Review 6.  Epigenetic mechanisms in breast cancer therapy and resistance.

Authors:  Liliana Garcia-Martinez; Yusheng Zhang; Yuichiro Nakata; Ho Lam Chan; Lluis Morey
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 14.919

7.  Anti-cancer potency by induced apoptosis by molecular docking P53, caspase, cyclin D1, cytotoxicity analysis and phagocytosis activity of trisindoline 1,3 and 4.

Authors:  Awik Puji Dyah Nurhayati; Andis Rihandoko; Arif Fadlan; Shabrina Syifa Ghaissani; Nurul Jadid; Edwin Setiawan
Journal:  Saudi Pharm J       Date:  2022-06-21       Impact factor: 4.562

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.